Saltar al contenido
Merck

T7947

Sigma-Aldrich

(R)-Tomoxetine hydrochloride

solid

Sinónimos:

(R)-N-Methyl-γ-(2-methyl­phenoxy)benzenepropanamine hydrochloride, Atomoxetine hydrochloride

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización

Seleccione un Tamaño

25 MG
MXP 12,396.00
100 MG
MXP 31,302.00

MXP 12,396.00


Check Cart for Availability

Solicitar un pedido a granel

Seleccione un Tamaño

Cambiar Vistas
25 MG
MXP 12,396.00
100 MG
MXP 31,302.00

About This Item

Fórmula empírica (notación de Hill):
C17H21NO · HCl
Número de CAS:
Peso molecular:
291.82
Número MDL:
Código UNSPSC:
12352200
ID de la sustancia en PubChem:
NACRES:
NA.77

MXP 12,396.00


Check Cart for Availability

Solicitar un pedido a granel

Formulario

solid

emisor

Eli Lilly

temp. de almacenamiento

2-8°C

cadena SMILES

CNCC[C@@H](OC1=CC=CC=C1C)C2=CC=CC=C2.[H]Cl

InChI

1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/m1./s1

Clave InChI

LUCXVPAZUDVVBT-UNTBIKODSA-N

Información sobre el gen

human ... SLC6A2(6530)

¿Está buscando productos similares? Visita Guía de comparación de productos

Aplicación

(R)-Tomoxetine hydrochloride has been used as a noradrenaline reuptake inhibitor:
  • to study the role of L-threo-3,4-dihydroxyphenylserine (L-DOPS) in the pathogenesis of Alzheimer′s disease in mice[1]
  • to study its effects on set shifting in rats[2]
  • to study its effects on rat brain as a result of its long-term use[3]

Acciones bioquímicas o fisiológicas

(R)-Tomoxetine hydrochloride is an efficient inhibitor of presynaptic norepinephrine transporters.[4] It also positively regulates the release of acetylcholine in the prefrontal cortex (PFC).[2] (R)-Tomoxetine hydrochloride binds to the serotonin (5-HT) transporter.[2] It is involved in blocking the cortical N-methyl-D-aspartate (NMDA) receptors.[2]. (R)-Tomoxetine hydrochloride exhibits therapeutic effects against attention-deficit/hyperactivity disorder (ADHD) and comorbid oppositional defiant disorder (ODD).[4]
Norepinephrine uptake blocker.

Características y beneficios

This compound is featured on the Biogenic Amine Transporters page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Equipo de protección personal

Eyeshields, Gloves, type N95 (US)


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Sergey Kalinin et al.
Neurobiology of aging, 33(8), 1651-1663 (2011-06-28)
Damage to noradrenergic neurons in the locus coeruleus (LC) is a hallmark of Alzheimer's disease (AD) and may contribute to disease progression. In 5xFAD transgenic mice, which accumulate amyloid burden at early ages, the LC undergoes stress as evidenced by
Romano Arcieri et al.
Journal of child and adolescent psychopharmacology, 22(6), 423-431 (2013-01-31)
The purpose of this study was to assess the cardiovascular effects of drugs used for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents treated in community care centers in Italy. This study was an open, prospective, observational study of youth with
Christina A Wilson et al.
Pharmacology, biochemistry, and behavior, 104, 47-61 (2013-01-05)
Rats repeatedly exposed to variable prenatal stress (PNS) exhibit behavioral signs that are similar to those manifested in several neuropsychiatric disorders such as deficits in attention and inhibitory control, and impairments in memory-related task performance. The purpose of the study
Himanshu P Upadhyaya et al.
Psychopharmacology, 226(2), 189-200 (2013-02-12)
Treatment of attention-deficit/hyperactivity disorder (ADHD) has for many years relied on psychostimulants, particularly various formulations of amphetamines and methylphenidate. These are central nervous system stimulants and are scheduled because of their abuse potential. Atomoxetine (atomoxetine hydrochloride; Strattera®) was approved in
Todd M Durell et al.
Journal of clinical psychopharmacology, 33(1), 45-54 (2013-01-02)
Attention-deficit/hyperactivity disorder (ADHD) is associated with significant impairment in multiple functional domains. This trial evaluated efficacy in ADHD symptoms and functional outcomes in young adults treated with atomoxetine. Young adults (18-30 years old) with ADHD were randomized to 12 weeks

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico